Optimi Health Gets Health Canada Export Permit for MDMA to Tel Aviv University

Optimi Health Corp., a notable Canadian manufacturer of pharmaceutical psychedelics with a Health Canada license, has made a groundbreaking stride in its international operations. On May 9, 2024, the company announced it had secured the necessary Export Permit from Health Canada to ship its in-house manufactured MDMA active pharmaceutical ingredient (API) to The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel, marking Optimi’s first international export.

The company's CEO, Bill Ciprick, expressed pride in this partnership, emphasizing its importance in advancing psychedelic research and innovation on a global level. He highlighted Optimi's capability to produce Good Manufacturing Practice (GMP) psychedelic pharmaceuticals on demand, and their commitment to supporting scientific exploration and therapeutic developments worldwide.

This collaboration, initially announced in March, aims to support a study conducted by IPR-TLV on the effects of MDMA on alcohol addiction. The shipment of MDMA API is a significant step in this joint effort, facilitating critical research that could lead to new treatments for addiction.

Jacob Safarik, Optimi Health's Chief Financial Officer, noted the complex procedures involved in obtaining an Export Permit for controlled substances. He acknowledged the collaborative efforts of various stakeholders, including IPR-TLV and Health Canada, which were essential in navigating the regulatory landscape to achieve this milestone.

Optimi Health’s MDMA-HCL is meticulously synthesized at the company's 10,000-square-foot facility in Princeton, British Columbia. The production process involves materials sourced through Optimi’s Health Canada Precursor License. To ensure the highest quality, the synthesized MDMA-HCL undergoes extensive testing both internally and through third-party analytical laboratories. The identity and purity of the compound, which exceeds 99%, have been confirmed using advanced analytical techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy and assay testing. Multiple batches of MDMA-HCL have been produced in multi-gram quantities to meet the requirements of the order.

Optimi Health Corp. stands out in the field of psychedelic pharmaceuticals, specializing in compounds like botanical psilocybin and MDMA, as well as functional mushrooms aimed at the health and wellness markets. The company operates with a mission to produce scalable psychedelic formulations designed to foster transformational human experiences. Optimi aspires to be the most trusted and compassionate supplier of safe drug candidates globally. Their products are cultivated and manufactured in two facilities spanning 20,000 square feet in Princeton, British Columbia. This recent achievement underscores Optimi's commitment to enhancing global psychedelic research and therapeutic innovation.